

Kimmo Taari

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2431457/publications.pdf>

Version: 2024-02-01

97
papers

4,093
citations

331538

21
h-index

118793

62
g-index

97
all docs

97
docs citations

97
times ranked

5231
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 1 | Outcomes of Screening for Prostate Cancer Among Men Who Use Statins. <i>JAMA Oncology</i> , 2022, 8, 61. | 3.4 | 6 |
| 2 | Population-based randomized trial of screening for clinically significant prostate cancer ProScreen: a pilot study. <i>BJU International</i> , 2022, 130, 193-199. | 1.3 | 13 |
| 3 | Anti-epileptic drugs and prostate cancer-specific mortality compared to non-users of anti-epileptic drugs in the Finnish Randomized Study of Screening for Prostate Cancer. <i>British Journal of Cancer</i> , 2022, , . | 2.9 | 1 |
| 4 | Inverse Association between Statin Use and Cancer Mortality Relates to Cholesterol Level. <i>Cancers</i> , 2022, 14, 2920. | 1.7 | 3 |
| 5 | Number of screening rounds attended and incidence of high-risk prostate cancer in the Finnish Randomized Study of Screening for Prostate Cancer (FinRSPC). <i>Cancer</i> , 2021, 127, 188-192. | 2.0 | 4 |
| 6 | Prognostic Index for Predicting Prostate Cancer Survival in a Randomized Screening Trial: Development and Validation. <i>Cancers</i> , 2021, 13, 435. | 1.7 | 3 |
| 7 | Antidiabetic Drugs and Prostate Cancer Prognosis in a Finnish Population-Based Cohort. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2021, 30, 982-989. | 1.1 | 3 |
| 8 | Antiepileptic drugs and prostate cancer risk in the Finnish Randomized Study of Screening for Prostate Cancer. <i>International Journal of Cancer</i> , 2021, 149, 307-315. | 2.3 | 3 |
| 9 | Prostate cancer prognosis after initiation of androgen deprivation therapy among statin users. A population-based cohort study. <i>Prostate Cancer and Prostatic Diseases</i> , 2021, 24, 917-924. | 2.0 | 24 |
| 10 | Outcomes of prostate cancer screening among men using antidiabetic medication. <i>Scientific Reports</i> , 2021, 11, 7363. | 1.6 | 0 |
| 11 | Estimating the rate of overdiagnosis with prostate cancer screening: evidence from the Finnish component of the European Randomized Study of Screening for Prostate Cancer. <i>Cancer Causes and Control</i> , 2021, 32, 1299-1313. | 0.8 | 6 |
| 12 | Digital rectal examination in prostate cancer screening at PSA level 3.0-3.9 ng/ml: long-term results from a randomized trial. <i>Scandinavian Journal of Urology</i> , 2021, 55, 348-353. | 0.6 | 8 |
| 13 | Health-Related Quality of Life and Survival in Prostate Cancer Patients in a Real-World Setting. <i>Urologia Internationalis</i> , 2020, 104, 939-947. | 0.6 | 4 |
| 14 | Expected impact of MRI-related interreader variability on ProScreen prostate cancer screening trial: a pre-trial validation study. <i>Cancer Imaging</i> , 2020, 20, 72. | 1.2 | 10 |
| 15 | Serum tumour associated trypsin inhibitor, as a biomarker for survival in renal cell carcinoma. <i>Scandinavian Journal of Urology</i> , 2020, 54, 413-419. | 0.6 | 3 |
| 16 | Prostate cancer risk prediction using a polygenic risk score. <i>Scientific Reports</i> , 2020, 10, 17075. | 1.6 | 39 |
| 17 | Long-term health-related quality of life among men with prostate cancer in the Finnish randomized study of screening for prostate cancer. <i>Cancer Medicine</i> , 2020, 9, 5643-5654. | 1.3 | 4 |
| 18 | Antihypertensive drug use and prostate cancer-specific mortality in Finnish men. <i>PLoS ONE</i> , 2020, 15, e0234269. | 1.1 | 12 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 19 | Patients' education level and treatment modality for prostate cancer in the Finnish Randomized Study of Screening for Prostate Cancer. <i>European Journal of Cancer</i> , 2020, 130, 204-210. | 1.3 | 6 |
| 20 | Antihypertensive drug use and prostate cancer-specific mortality in Finnish men. , 2020, 15, e0234269. | | 0 |
| 21 | Antihypertensive drug use and prostate cancer-specific mortality in Finnish men. , 2020, 15, e0234269. | | 0 |
| 22 | Antihypertensive drug use and prostate cancer-specific mortality in Finnish men. , 2020, 15, e0234269. | | 0 |
| 23 | Antihypertensive drug use and prostate cancer-specific mortality in Finnish men. , 2020, 15, e0234269. | | 0 |
| 24 | Clonal heterogeneity influences drug responsiveness in renal cancer assessed by <i>ex vivo</i> drug testing of multiple patient-derived cancer cells. <i>International Journal of Cancer</i> , 2019, 144, 1356-1366. | 2.3 | 29 |
| 25 | Anticoagulants and cancer mortality in the Finnish randomized study of screening for prostate cancer. <i>Cancer Causes and Control</i> , 2019, 30, 877-888. | 0.8 | 5 |
| 26 | Randomised Trial of Adjuvant Radiotherapy Following Radical Prostatectomy Versus Radical Prostatectomy Alone in Prostate Cancer Patients with Positive Margins or Extracapsular Extension. <i>European Urology</i> , 2019, 76, 586-595. | 0.9 | 68 |
| 27 | &p&g&t;Charlson Comorbidity Index Based On Hospital Episode Statistics Performs Adequately In Predicting Mortality, But Its Discriminative Ability Diminishes Over Time&p&g&t;. <i>Clinical Epidemiology</i> , 2019, Volume 11, 923-932. | 1.5 | 37 |
| 28 | Blood glucose, glucose balance, and disease-specific survival after prostate cancer diagnosis in the Finnish Randomized Study of Screening for Prostate Cancer. <i>Prostate Cancer and Prostatic Diseases</i> , 2019, 22, 453-460. | 2.0 | 11 |
| 29 | Evolving Clinical Picture of Renal Cell Carcinoma: A Population-Based Study from Helsinki. <i>Urologia Internationalis</i> , 2019, 102, 390-398. | 0.6 | 1 |
| 30 | Allopurinol and the risk of prostate cancer in a Finnish population-based cohort. <i>Prostate Cancer and Prostatic Diseases</i> , 2019, 22, 483-490. | 2.0 | 6 |
| 31 | The association of financial difficulties and out-of-pocket payments with health-related quality of life among breast, prostate and colorectal cancer patients. <i>Acta Oncologica</i> , 2019, 58, 1062-1068. | 0.8 | 22 |
| 32 | A 16-yr Follow-up of the European Randomized study of Screening for Prostate Cancer. <i>European Urology</i> , 2019, 76, 43-51. | 0.9 | 359 |
| 33 | Cost-effectiveness analysis of PSA-based mass screening: Evidence from a randomised controlled trial combined with register data. <i>PLoS ONE</i> , 2019, 14, e0224479. | 1.1 | 6 |
| 34 | Serum cholesterol and prostate cancer risk in the Finnish randomized study of screening for prostate cancer. <i>Prostate Cancer and Prostatic Diseases</i> , 2019, 22, 66-76. | 2.0 | 28 |
| 35 | Costs in Different States of Breast Cancer. <i>Anticancer Research</i> , 2019, 39, 353-359. | 0.5 | 6 |
| 36 | Bias-corrected estimates of effects of PSA screening decisions on the risk of prostate cancer diagnosis and death: Analysis of the Finnish randomized study of screening for prostate cancer. <i>International Journal of Cancer</i> , 2019, 145, 632-638. | 2.3 | 3 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 37 | The Number of Screening Cycles Needed to Reduce Prostate Cancer Mortality in the Finnish Section of the European Randomized Study of Prostate Cancer (ERSPC). <i>Clinical Cancer Research</i> , 2019, 25, 839-843. | 3.2 | 7 |
| 38 | A Four-kallikrein Panel and Î²-Microseminoprotein in Predicting High-grade Prostate Cancer on Biopsy: An Independent Replication from the Finnish Section of the European Randomized Study of Screening for Prostate Cancer. <i>European Urology Focus</i> , 2019, 5, 561-567. | 1.6 | 8 |
| 39 | Title is missing!. , 2019, 14, e0224479. | | 0 |
| 40 | Title is missing!. , 2019, 14, e0224479. | | 0 |
| 41 | Title is missing!. , 2019, 14, e0224479. | | 0 |
| 42 | Title is missing!. , 2019, 14, e0224479. | | 0 |
| 43 | Fasting blood glucose, glycaemic control and prostate cancer risk in the Finnish Randomized Study of Screening for Prostate Cancer. <i>British Journal of Cancer</i> , 2018, 118, 1248-1254. | 2.9 | 18 |
| 44 | Allopurinol and risk of benign prostatic hyperplasia in a Finnish population-based cohort. <i>Prostate Cancer and Prostatic Diseases</i> , 2018, 21, 373-378. | 2.0 | 7 |
| 45 | Costs of screening for prostate cancer: Evidence from the Finnish Randomised Study of Screening for Prostate Cancer after 20-year follow-up using register data. <i>European Journal of Cancer</i> , 2018, 93, 108-118. | 1.3 | 4 |
| 46 | Outcomes of Prostate-specific Antigen-based Prostate Cancer Screening Among Men Using Nonsteroidal Anti-inflammatory Drugs. <i>European Urology Focus</i> , 2018, 4, 851-857. | 1.6 | 5 |
| 47 | Renal Tumor Invasion Depth and Diameter are the Two Most Accurate Anatomical Features Regarding the Choice of Radical Versus Partial Nephrectomy. <i>Scandinavian Journal of Surgery</i> , 2018, 107, 54-61. | 1.3 | 4 |
| 48 | The indirect costs of palliative care in end-stage cancer: A real-life longitudinal register- and questionnaire-based study. <i>Palliative Medicine</i> , 2018, 32, 493-499. | 1.3 | 18 |
| 49 | Prognostic factors of prostate cancer mortality in a Finnish randomized screening trial. <i>International Journal of Urology</i> , 2018, 25, 270-276. | 0.5 | 11 |
| 50 | Health-related quality of life in different states of breast cancer – comparing different instruments. <i>Acta OncolÃ³gica</i> , 2018, 57, 622-628. | 0.8 | 41 |
| 51 | Antihypertensive drugs and prostate cancer risk in a Finnish population-based cohort. <i>Scandinavian Journal of Urology</i> , 2018, 52, 321-327. | 0.6 | 9 |
| 52 | Surgery for metastases of renal cell carcinoma: outcome of treatments and preliminary assessment of Leuven-Udine prognostic groups in the targeted therapy era. <i>Scandinavian Journal of Urology</i> , 2018, 52, 419-426. | 0.6 | 16 |
| 53 | Cancer mortality does not differ by antiarrhythmic drug use: A population-based cohort of Finnish men. <i>Scientific Reports</i> , 2018, 8, 10308. | 1.6 | 2 |
| 54 | Estimate of Opportunistic Prostate Specific Antigen Testing in the Finnish Randomized Study of Screening for Prostate Cancer. <i>Journal of Urology</i> , 2017, 198, 50-57. | 0.2 | 24 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 55 | Antidiabetic drug use and prostate cancer risk in the Finnish Randomized Study of Screening for Prostate Cancer. <i>Scandinavian Journal of Urology</i> , 2017, 51, 5-12. | 0.6 | 41 |
| 56 | Patients' perceptions of the negative effects following different prostate cancer treatments and the impact on psychological well-being: a nationwide survey. <i>British Journal of Cancer</i> , 2017, 116, 864-873. | 2.9 | 56 |
| 57 | Outcomes of Prostate Cancer Screening by 5 α -Reductase Inhibitor Use. <i>Journal of Urology</i> , 2017, 198, 305-309. | 0.2 | 3 |
| 58 | The effect of nonsteroidal anti-inflammatory drugs on risk of benign prostatic hyperplasia. <i>Prostate</i> , 2017, 77, 1029-1035. | 1.2 | 8 |
| 59 | A randomized trial of early detection of clinically significant prostate cancer (ProScreen): study design and rationale. <i>European Journal of Epidemiology</i> , 2017, 32, 521-527. | 2.5 | 36 |
| 60 | An Intraprostatic Modified Release Formulation of Antiandrogen 2-Hydroxyflutamide for Localized Prostate Cancer. <i>Journal of Urology</i> , 2017, 198, 1333-1339. | 0.2 | 7 |
| 61 | Health-related quality of life among prostate cancer patients: real-life situation at the beginning of treatment. <i>Scandinavian Journal of Urology</i> , 2017, 51, 13-19. | 0.6 | 12 |
| 62 | Adjuvant Weekly Girentuximab Following Nephrectomy for High-Risk Renal Cell Carcinoma. <i>JAMA Oncology</i> , 2017, 3, 913. | 3.4 | 107 |
| 63 | Statin Use and Prostate Cancer Survival in the Finnish Randomized Study of Screening for Prostate Cancer. <i>European Urology Focus</i> , 2017, 3, 212-220. | 1.6 | 37 |
| 64 | Prostate cancer-specific survival among warfarin users in the Finnish Randomized Study of Screening for Prostate Cancer. <i>BMC Cancer</i> , 2017, 17, 585. | 1.1 | 9 |
| 65 | 5 α -Reductase inhibitor use and prostate cancer survival in the Finnish Prostate Cancer Screening Trial. <i>International Journal of Cancer</i> , 2016, 138, 2820-2828. | 2.3 | 14 |
| 66 | USE OF PATIENT ASSESSED HEALTH-RELATED QUALITY OF LIFE INSTRUMENTS IN PROSTATE CANCER RESEARCH: A SYSTEMATIC REVIEW OF THE LITERATURE 2002-2015. <i>International Journal of Technology Assessment in Health Care</i> , 2016, 32, 97-106. | 0.2 | 10 |
| 67 | Outcome of surgery for patients with renal cell carcinoma and tumour thrombus in the era of modern targeted therapy. <i>Scandinavian Journal of Urology</i> , 2016, 50, 380-386. | 0.6 | 12 |
| 68 | Number of Screening Rounds and Postscreening Prostate Cancer Incidence: Results from the Finnish Section of the European Randomized Study of Screening for Prostate Cancer Study. <i>European Urology</i> , 2016, 70, 499-505. | 0.9 | 6 |
| 69 | Estimating bias in causes of death ascertainment in the Finnish Randomized Study of Screening for Prostate Cancer. <i>Cancer Epidemiology</i> , 2016, 45, 1-5. | 0.8 | 14 |
| 70 | Warfarin use and prostate cancer risk in the Finnish Randomized Study of Screening for Prostate Cancer. <i>Scandinavian Journal of Urology</i> , 2016, 50, 413-419. | 0.6 | 14 |
| 71 | Digoxin and prostate cancer survival in the Finnish Randomized Study of Screening for Prostate Cancer. <i>British Journal of Cancer</i> , 2016, 115, 1289-1295. | 2.9 | 12 |
| 72 | Prostate cancer risk among users of digoxin and other antiarrhythmic drugs in the Finnish Prostate Cancer Screening Trial. <i>Cancer Causes and Control</i> , 2016, 27, 157-164. | 0.8 | 11 |

| # | ARTICLE | IF | CITATIONS |
|----|--|------|-----------|
| 73 | Costs in different states of prostate cancer. <i>Acta Oncologica</i> , 2016, 55, 30-37. | 0.8 | 11 |
| 74 | Absolute Effect of Prostate Cancer Screening: Balance of Benefits and Harms by Center within the European Randomized Study of Prostate Cancer Screening. <i>Clinical Cancer Research</i> , 2016, 22, 243-249. | 3.2 | 35 |
| 75 | Non-Steroidal Anti-Inflammatory Drugs and Cancer Death in the Finnish Prostate Cancer Screening Trial. <i>PLoS ONE</i> , 2016, 11, e0153413. | 1.1 | 18 |
| 76 | Use of non-steroidal anti-inflammatory drugs and prostate cancer survival in the finnish prostate cancer screening trial. <i>Prostate</i> , 2015, 75, 1394-1402. | 1.2 | 19 |
| 77 | Patient experiences at diagnosis and psychological well-being in prostate cancer: A Finnish national survey. <i>European Journal of Oncology Nursing</i> , 2015, 19, 220-229. | 0.9 | 34 |
| 78 | Polymorphisms of Genes Involved in Glucose and Energy Metabolic Pathways and Prostate Cancer: Interplay with Metformin. <i>European Urology</i> , 2015, 68, 1089-1097. | 0.9 | 7 |
| 79 | Hand-assisted laparoscopic versus open partial nephrectomy in patients with T1 renal tumor: Comparative perioperative, functional and oncological outcome. <i>Scandinavian Journal of Urology</i> , 2015, 49, 446-452. | 0.6 | 1 |
| 80 | Prostate cancer risk and nonsteroidal antiinflammatory drug use in the Finnish prostate cancer screening trial. <i>British Journal of Cancer</i> , 2014, 111, 1421-1431. | 2.9 | 26 |
| 81 | Screening and prostate cancer mortality: results of the European Randomised Study of Screening for Prostate Cancer (ERSPC) at 13 years of follow-up. <i>Lancet, The</i> , 2014, 384, 2027-2035. | 6.3 | 1,261 |
| 82 | Health-Related Quality of Life in the Finnish Trial of Screening for Prostate Cancer. <i>European Urology</i> , 2014, 65, 39-47. | 0.9 | 21 |
| 83 | Prostate-Cancer Mortality at 11 Years of Follow-up. <i>New England Journal of Medicine</i> , 2012, 366, 981-990. | 13.9 | 1,105 |
| 84 | Laparoscopic versus Open Nephrectomy for Renal Cell Carcinoma?. <i>Scandinavian Journal of Surgery</i> , 2004, 93, 132-136. | 1.3 | 9 |
| 85 | Optimal timing of post-biopsy MR imaging of the prostate. <i>Acta Radiologica</i> , 2001, 42, 70-73. | 0.5 | 70 |
| 86 | Prostatic MR imaging: Accuracy in differentiating cancer from other prostatic disorders. <i>Acta Radiologica</i> , 2001, 42, 348-354. | 0.5 | 70 |
| 87 | Magnetic resonance imaging of prostatic cancer: Does detection vary between high and low gleason score tumors?. <i>Prostate</i> , 2000, 43, 43-48. | 1.2 | 33 |
| 88 | Holmium:YAG Laser for Urinary Stones. <i>Scandinavian Journal of Urology and Nephrology</i> , 1999, 33, 295-298. | 1.4 | 8 |
| 89 | Radioiodinated estramustine phosphate and estramustine binding protein Antibody accumulate in the prostate of a mouse. , 1997, 32, 1-8. | | 1 |
| 90 | Partial nephrectomy with a combined CO2 and Nd:YAG laser: Experimental study in pigs. <i>Lasers in Surgery and Medicine</i> , 1994, 14, 23-26. | 1.1 | 14 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 91 | Shoulder pain due to rupture of a calyceal diverticulum as an acute sign of prostatic hyperplasia. British Journal of Urology, 1994, 73, 458-459. | 0.1 | 3 |
| 92 | Contact fibre Nd: YAG laser for partial nephrectomy: experimental study in pigs. Urological Research, 1993, 21, 301-304. | 1.5 | 6 |
| 93 | Parenchyma-conserving surgery for renal cell carcinoma. Annales Chirurgiae Et Gynaecologiae Supplementum, 1993, 206, 54-8. | 0.0 | 2 |
| 94 | Morphological Effects of Photodynamic Therapy on Rabbit Bladder Using Photofrin II and Photosan Intravesically and Intravenously. British Journal of Urology, 1992, 70, 616-621. | 0.1 | 13 |
| 95 | Renal Function after Partial Nephrectomy with the Nd:YAG Laser Experimental Study in Piglets. British Journal of Urology, 1991, 68, 459-462. | 0.1 | 5 |
| 96 | Efficacy and Complications of the ND:YAG Laser in Partial Nephrectomy: Experimental Study in Piglets. Scandinavian Journal of Urology and Nephrology, 1991, 25, 303-306. | 1.4 | 5 |
| 97 | Effect of alcohol on bladder function: A uroflowmetric and cystometric study. Neurourology and Urodynamics, 1990, 9, 591-594. | 0.8 | 0 |